C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus

REDWOOD CITY, Calif. – June 7, 2016 – C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett’s esophagus.

Click here to see full release.